Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone512-501-2444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings DateN/A
OptionableNot Optionable
Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Pain Therapeutics shares reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics, Inc. (NASDAQ:PTIE) released its earnings results on Monday, March, 25th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.57. View Pain Therapeutics' Earnings History.
Has Pain Therapeutics been receiving favorable news coverage?
Press coverage about PTIE stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pain Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Pain Therapeutics.
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Inflarx (IFRX), Alpine Immune Sciences (ALPN), Entasis Therapeutics (ETTX), Otonomy (OTIC), Acasti Pharma (ACST), Generex Biotechnology (GNBT), Merrimack Pharmaceuticals (MACK), VERONA PHARMA P/S (VRNA), Unum Therapeutics (UMRX), SCYNEXIS (SCYX), Relmada Therapeutics (RLMD), Ovid Therapeutics (OVID), Spring Bank Pharmaceuticals (SBPH), vTv Therapeutics (VTVT) and Aravive (ARAV).
What other stocks do shareholders of Pain Therapeutics own?
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
- Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
How do I buy shares of Pain Therapeutics?
Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of PTIE stock can currently be purchased for approximately $1.24.
How big of a company is Pain Therapeutics?
What is Pain Therapeutics' official website?
How can I contact Pain Therapeutics?
Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444 or via email at [email protected]
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
